A Phase 2, randomized, partially blinded, controlled, doseranging study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VEL-101 in kidney transplant recipients. (RENGEVITY-201)
VEL-101 (VELOXIS) to Prevent Rejection After Kidney Transplantation
Sponsor: Veloxis Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: ACYY0969
U.S. Govt. ID: NCT07290777
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-transplant to prevent rejection. Participants will be followed for 12 months, with the possibility of extending treatment beyond 12 months. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Lloyd Ratner, MD, MPH, FACS
Do You Qualify?
Are you at least 18 years old? Yes No
Are you on the kidney transplant waiting list? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE